Mar 29, 2023 / 02:30PM GMT
Paul Matteis - Stifel Financial Corp. - Analyst
Great. Thanks very much. It's my pleasure to be moderating this chat with Tony Coles, CEO of Cerevel. Tony, it's always great to see you.
We'll have a lot of specific stuff to get into. But maybe we can start with you just giving a quick update on the R&D portfolio, specifically the muscarinic, and then we can get into Q&A. So thanks again.
Tony Coles - Cerevel Therapeutics Holdings, Inc. - Chairperson of the Board of Directors & CEO
Well, Paul, always good to be with you. Thank you for having us. Look, the emraclidine program suggests us to start -- there is -- it's doing very, very well. We are currently enrolling the two large Phase 2s. They're still on track for a data readout in the first half of 2024.
Really importantly, for that particular program, we finished the very important risk-reducing trial, which was to look at this question of elevation in blood pressure. And that was clean, read out positively at the end of last year. So we're really encouraged by that.
We
Cerevel Therapeutics Holdings Inc at Stifel CNS Days (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot